Effect of CTLA-4 overexpression on response to ipilimumab in melanoma.

Abstract Poster

Authors

null

Mary Nesline

OmniSeq, Inc., Buffalo, NY

Mary Nesline, Igor Puzanov, Marc S. Ernstoff, Sarabjot Pabla, Jeffrey M. Conroy, Sean T. Glenn, Antonios Papanicolau-Sengos, Blake Burgher, Vincent Giamo, Paul DePietro, Jonathan Andreas, Maochun Qin, Felicia L. Lenzo, Mark Gardner, Carl Morrison, Grace Dy

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO-SITC Clinical Immuno-Oncology Symposium

Session Type

Poster Session

Session Title

Poster Session A

Track

Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Breast and Gynecologic Cancers,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Oncolytic Viruses,Hematologic Malignancies

Sub Track

Immune Checkpoints and Stimulatory Receptors

Citation

J Clin Oncol 36, 2018 (suppl 5S; abstr 190)

DOI

10.1200/JCO.2018.36.5_suppl.190

Abstract #

190

Poster Bd #

J7

Abstract Disclosures

Similar Posters

First Author: Zeynep Eroglu

First Author: Max Jameson-Lee

First Author: Vanessa Anne Eulo

Poster

2020 ASCO Virtual Scientific Program

A phase II single-arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated classical Kaposi sarcoma (CKS).

A phase II single-arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated classical Kaposi sarcoma (CKS).

First Author: Alona Zer